# A Non-Interventional Study PASS to Characterize Secondary Malignancies of Tcell Origin Following Tisagenlecleucel Therapy

> **NCT07378969** · — · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 30 (estimated)

## Conditions studied

- Secondary Malignancies of T-cell Origin

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07378969
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-23
- **Primary completion:** 2039-08-31
- **Final completion:** 2039-08-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07378969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07378969, "A Non-Interventional Study PASS to Characterize Secondary Malignancies of Tcell Origin Following Tisagenlecleucel Therapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07378969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*